Sonnet Historical Cash Flow
| SONN Stock | USD 2.41 0.20 7.66% |
Analysis of Sonnet Biotherapeutics cash flow over time is an excellent tool to project Sonnet Biotherapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 5.1 K or Other Cashflows From Financing Activities of 2.1 M as it is a great indicator of Sonnet Biotherapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Sonnet Biotherapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Sonnet Biotherapeutics is a good buy for the upcoming year.
Sonnet |
About Sonnet Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Sonnet balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Sonnet's non-liquid assets can be easily converted into cash.
Sonnet Biotherapeutics Cash Flow Chart
Add Fundamental
Change Receivables
The difference in the amount of accounts receivable from one accounting period to the next. A positive number indicates an increase in receivables, while a negative number indicates a decrease.Most accounts from Sonnet Biotherapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Sonnet Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonnet Biotherapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, Sonnet Biotherapeutics' Total Cashflows From Investing Activities is very stable compared to the past year. As of the 4th of December 2024, Cash Flows Other Operating is likely to grow to about 2 M, while Sale Purchase Of Stock is likely to drop about 167.2 K.
Sonnet Biotherapeutics cash flow statement Correlations
Click cells to compare fundamentals
Sonnet Biotherapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Sonnet Biotherapeutics cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Begin Period Cash Flow | 438.5K | 5.4K | 7.3M | 27.6M | 3.1M | 5.1K | |
| Capital Expenditures | 1.7M | 2.4M | 3.6K | 896.5K | 443.3K | 2.5M | |
| Total Cash From Operating Activities | (1.1M) | (2.2M) | (22.6M) | (27.7M) | (21.3M) | (2.3M) | |
| End Period Cash Flow | 524.1K | 35.7K | 27.6M | 3.1M | 2.3M | 33.9K | |
| Net Borrowings | 303.3K | (355.2K) | (526.1K) | (20.4K) | (473.5K) | (449.8K) | |
| Total Cashflows From Investing Activities | (2.4M) | 678.7K | (3.6K) | (896.5K) | 780.5K | 819.5K | |
| Change To Netincome | 1.5M | 8.6M | 1.3M | 1.8M | 9.9M | 10.4M | |
| Change To Liabilities | 2.6M | 155.9K | 1.7M | 621.1K | 179.3K | 170.3K |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonnet Biotherapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonnet Biotherapeutics. If investors know Sonnet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonnet Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.96) | Revenue Per Share 0.019 | Quarterly Revenue Growth (0.50) | Return On Assets (0.97) | Return On Equity (2.65) |
The market value of Sonnet Biotherapeutics is measured differently than its book value, which is the value of Sonnet that is recorded on the company's balance sheet. Investors also form their own opinion of Sonnet Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sonnet Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonnet Biotherapeutics' market value can be influenced by many factors that don't directly affect Sonnet Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sonnet Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonnet Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonnet Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.